aTyr Pharma is a biotherapeutics company engaged in the discovery and clinical development of innovative medicines based on novel immunological pathways. We have concentrated our research and development efforts on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. We have built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. We are focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family, one of the synthetase genes. ATYR1923 is a clinical-stage product candidate, based on the Resokine pathway, which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases.
Our founders, Paul Schimmel, Ph.D. and Xiang-Lei Yang, Ph.D., leading aminoacyl tRNA synthetase (aaRS) researchers at The Scripps Research Institute in San Diego, California, discovered the potential extracellular functionality of tRNA synthetases, along with our scientists in San Diego and Hong Kong.
By leveraging our vast patent estate of this newly discovered biology, we aim to build a proprietary pipeline of novel product candidates autonomously and with collaborators.
Click here to learn more about extracellular tRNA synthetase Biology.